 |
|
| Pagina dedicata alle informazioni sui farmaci di competenza dell'EMA, relativa alle autorizzazioni e alle segnalazioni di farmacovigilanza | |
EMA: Documentazione sui farmaci
NUOVI FARMACI, SEGNALAZIONI EMA
-
Human medicines European public assessment report (EPAR): Skojoy, aflibercept, Status: Application withdrawn
Human medicines European public assessment report (EPAR): Skojoy, aflibercept, Status: Application withdrawn
Human medicines European public assessment report (EPAR): Skojoy, aflibercept, Status: Application withdrawn
Source: New medicines and opinions: human
Created on: Apr 14, 2025 | 11:54 am
New medicines and opinions: human | Apr 14, 2025 | 11:54 am -
Human medicines European public assessment report (EPAR): Kisunla, donanemab, Status: Opinion under re-examination
Human medicines European public assessment report (EPAR): Kisunla, donanemab, Status: Opinion under re-examination
Human medicines European public assessment report (EPAR): Kisunla, donanemab, Status: Opinion under re-examination
Source: New medicines and opinions: human
Created on: Apr 11, 2025 | 12:45 pm
New medicines and opinions: human | Apr 11, 2025 | 12:45 pm -
Human medicines European public assessment report (EPAR): Cinainu, dry aqueous extract of paullinia cupana seed,dry hydroethanolic extract of theobroma cacao seed,liquid ethanolic extract 30 per cent (W/W) of Allium cepa fresh bulb and Citrus limon fresh fruit, Status: Application withdrawn
Human medicines European public assessment report (EPAR): Cinainu, dry aqueous extract of paullinia cupana seed,dry hydroethanolic extract of theobroma cacao seed,liquid ethanolic extract 30 per cent (W/W) of Allium cepa fresh bulb and Citrus limon fresh fruit, Status: Application withdrawn
Human medicines European public assessment report (EPAR): Cinainu, dry aqueous extract of paullinia cupana seed,dry hydroethanolic extract of theobroma cacao seed,liquid ethanolic extract 30 per cent (W/W) of Allium cepa fresh bulb and Citrus limon fresh fruit, Status: Application withdrawn
Source: New medicines and opinions: human
Created on: Mar 28, 2025 | 12:00 pm
New medicines and opinions: human | Mar 28, 2025 | 12:00 pm -
Human medicines European public assessment report (EPAR): Ryjunea, Atropine sulfate, Status: Opinion
Human medicines European public assessment report (EPAR): Ryjunea, Atropine sulfate, Status: Opinion
Human medicines European public assessment report (EPAR): Ryjunea, Atropine sulfate, Status: Opinion
Source: New medicines and opinions: human
Created on: Mar 28, 2025 | 12:00 pm
New medicines and opinions: human | Mar 28, 2025 | 12:00 pm -
Human medicines European public assessment report (EPAR): Qoyvolma, ustekinumab, Status: Opinion
Human medicines European public assessment report (EPAR): Qoyvolma, ustekinumab, Status: Opinion
Human medicines European public assessment report (EPAR): Qoyvolma, ustekinumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Mar 28, 2025 | 12:00 pm
New medicines and opinions: human | Mar 28, 2025 | 12:00 pm -
Human medicines European public assessment report (EPAR): Jubereq, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Jubereq, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Jubereq, denosumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Mar 28, 2025 | 12:00 pm
New medicines and opinions: human | Mar 28, 2025 | 12:00 pm -
Human medicines European public assessment report (EPAR): Xoanacyl, ferric citrate coordination complex, Status: Opinion
Human medicines European public assessment report (EPAR): Xoanacyl, ferric citrate coordination complex, Status: Opinion
Human medicines European public assessment report (EPAR): Xoanacyl, ferric citrate coordination complex, Status: Opinion
Source: New medicines and opinions: human
Created on: Mar 28, 2025 | 12:00 pm
New medicines and opinions: human | Mar 28, 2025 | 12:00 pm -
Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Status: Opinion
Source: New medicines and opinions: human
Created on: Mar 28, 2025 | 12:00 pm
New medicines and opinions: human | Mar 28, 2025 | 12:00 pm -
Human medicines European public assessment report (EPAR): Eydenzelt, aflibercept, Date of authorisation: 12/02/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Eydenzelt, aflibercept, Date of authorisation: 12/02/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Eydenzelt, aflibercept, Date of authorisation: 12/02/2025, Status: Authorised
Source: New medicines and opinions: human
Created on: Mar 27, 2025 | 13:45 pm
New medicines and opinions: human | Mar 27, 2025 | 13:45 pm -
Human medicines European public assessment report (EPAR): Vimkunya, Chikungunya vaccine (recombinant, adsorbed), Date of authorisation: 28/02/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Vimkunya, Chikungunya vaccine (recombinant, adsorbed), Date of authorisation: 28/02/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Vimkunya, Chikungunya vaccine (recombinant, adsorbed), Date of authorisation: 28/02/2025, Status: Authorised
Source: New medicines and opinions: human
Created on: Mar 24, 2025 | 11:30 am
New medicines and opinions: human | Mar 24, 2025 | 11:30 am